Evidence map›Paper›PMID 41622133›Full record

ArticleBMC cancer2026

Evaluation of variations in urine laminin-γ2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.

Kimito Osaka, Takeshi Kishida, Susumu Umemoto, Takashi Karashima, Masatoshi Nakagawa, Eisaku Yoshida, Toru Yoshimura, Masahiko Sakaguchi, Keiji Inoue, Naohiko Koshikawa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kimito OsakaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Takeshi KishidaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Susumu UmemotoDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Takashi KarashimaDepartment of Urology, Kochi Medical School, Nankoku, Japan. karasima@kochi-u.ac.jp.ORCID http://orcid.org/0000-0001-7338-8059
Masatoshi NakagawaDiagnostic Division, Abbott Japan LLC, Chiba, Japan.
Eisaku YoshidaDiagnostic Division, Abbott Japan LLC, Chiba, Japan.
Toru YoshimuraDiagnostic Division, Abbott Japan LLC, Chiba, Japan.
Masahiko SakaguchiIntegrated Center for Advanced Medical Technologies, Kochi Medical School, Nankoku, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Naohiko KoshikawaKanagawa Cancer Center Research Institute, Yokohama, Japan.
Motoharu SeikiDivision of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Taro ShuinDepartment of Urology, Kochi Medical School, Nankoku, Japan.

Funding

Japan Agency for Medical Research and Development 5lm0103002j0004 (B29)
6 · The paper itself

Abstract

backgroundWe have previously reported urine laminin-γ2 monomer (Lm-γ2m) as a diagnostic biomarker for patients with non-muscle-invasive bladder cancer (NMIBC). However, Lm-γ2m has not been evaluated as a prognostic biomarker for patients with NMIBC after transurethral resection of bladder tumor (TURBT). This study aimed to clarify whether urine Lm-γ2m offers a useful prognostic biomarker for patients with NMIBC after TURBT.

methodsParticipants comprised 41 patients with NMIBC. Urine Lm-γ2m was prospectively measured before and 3 months after TURBT and values were compared. Traditional urine tumor markers such as urine nuclear matrix protein 22 and cytology were also evaluated before and after TURBT. Patients were stratified by the presence of recurrence within 1 year after TURBT and values of urine Lm-γ2m before and after TURBT were analyzed.

resultsMean urine Lm-γ2m values were significantly decreased after TURBT compared to before surgery. Mean urine Lm-γ2m before and after TURBT were higher in patients with recurrence within 1 year after surgery than in patients without recurrence. Urine Lm-γ2m before TURBT was also important to predict prognosis in patients with NMIBC treated using TURBT.

conclusionsThese results suggest urine Lm-γ2m as a potentially useful biomarker for NMIBC before and after TURBT.

Indexed as

Biomarkers, TumorLamininNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisTransurethral Resection of BladderBiomarkers, TumorLAMC2 protein, humanLamininBladder cancer, nonInvasive bladder cancer, lamininMuscleγ2 monomer, biomarkerγ2, urine laminin

Identifiers

PMID41622133
PMCPMC12958644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.